Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $119,145.06 in Stock

Key Points

• CeriBell CTO Raymond Woo sold 4,887 shares at an average price of $24.38, generating $119,145.06 and reducing his direct ownership by 2.35% to 203,118 shares.
• CeriBell shares traded near $23.69, with the company valued at approximately $909 million. Its latest quarterly loss of $0.51 per share missed estimates, although revenue of $28.1 million exceeded forecasts.
• Institutional investors—including BlackRock, Bank of New York Mellon, and TimesSquare Capital—initiated positions, while analysts maintained a broadly positive view with a “Moderate Buy” consensus and a $27 average price target.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $24.38, for a total transaction of $119,145.06. Following the completion of the sale, the chief technology officer directly owned 203,118 shares of the company's stock, valued at approximately $4,952,016.84. This trade represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total transaction of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.08 during mid-day trading on Friday, hitting $23.69. The company had a trading volume of 305,317 shares, compared to its average volume of 344,626. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.63. The firm has a market cap of $909.17 million, a P/E ratio of -13.46 and a beta of 0.94. The business's 50-day simple moving average is $22.64 and its 200-day simple moving average is $20.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. As a group, analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CBLL. TimesSquare Capital Management LLC acquired a new stake in CeriBell during the 2nd quarter valued at $15,182,000. Bank of New York Mellon Corp acquired a new position in CeriBell in the second quarter worth $17,437,000. BlackRock Inc. bought a new stake in shares of CeriBell during the second quarter worth $37,657,000. Deutsche Bank AG acquired a new stake in shares of CeriBell in the second quarter valued at $1,742,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of CeriBell in the second quarter valued at $2,078,000.

Analyst Ratings Changes

CBLL has been the topic of a number of recent research reports. Barclays upgraded shares of CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. TD Cowen increased their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a research note on Friday. Canaccord Genuity Group raised their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Raymond James Financial reiterated a "strong-buy" rating and set a $29.00 target price on shares of CeriBell in a research report on Thursday, September 3rd. Finally, BTIG Research reissued a "buy" rating and issued a $30.00 target price on shares of CeriBell in a research note on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CeriBell has a consensus rating of "Moderate Buy" and a consensus target price of $27.00.

CeriBell Company Profile

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.